| pubmed-article:2313733 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2313733 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:2313733 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:2313733 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2313733 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:2313733 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:2313733 | pubmed:dateCreated | 1990-4-16 | lld:pubmed |
| pubmed-article:2313733 | pubmed:abstractText | Fifty-three women with breast cancer were treated with a new 16-week dose-intense, chemotherapy regimen. Patients with operable breast cancer with 10 or more histologically positive axillary nodes were treated with this five-drug regimen that incorporated the concepts of weekly chemotherapy, sequential administration of antimetabolites, and continuous infusion of fluorouracil (5-FU). The chemotherapy regimen consisted of eight cycles (each of 2 wk duration) of 100 mg of cyclophosphamide/m2 orally on days 1-7, 40 mg of doxorubicin/m2 intravenous (IV) on day 1, 100 mg of methotrexate/m2 IV on day 1 with 10 mg of leucovorin rescue/m2 every 6 hours for six oral doses on day 2, 1 mg of vincristine IV on day 1, and 600 mg of 5-FU/m2 IV at hour 20 over 2 hours. A continuous infusion of 300 mg of 5-FU/m2 per day was given IV on days 8-9 of each 2-week cycle. The doses and schedule of drug administration were designed to minimize dosage reduction and treatment delay. At a median follow-up of 17 months, there have been eight relapses in the 53 patients. The actuarial 3-year disease-free survival is 80% (95% confidence interval, 62% to 90%). The major side effects were attributable to myelosuppression. Absolute neutrophil counts less than 250/microL were noted in 12 (23%) patients; seven patients (13%) required hospitalization for management of neutropenic fever. No treatment-related deaths occurred. Ninety-four percent of the planned doses were administered, and only 5% of the courses were delayed because of toxic reactions. The encouraging therapeutic data, manageable side effects, and our ability to deliver over 90% of the planned doses provide the rationale for a phase III comparison of this new dose-intense regimen and standard chemotherapy in patients with operable disease and positive axillary nodes. | lld:pubmed |
| pubmed-article:2313733 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2313733 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2313733 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2313733 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2313733 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2313733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2313733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2313733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2313733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2313733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2313733 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2313733 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2313733 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:2313733 | pubmed:issn | 0027-8874 | lld:pubmed |
| pubmed-article:2313733 | pubmed:author | pubmed-author:AbeloffM DMD | lld:pubmed |
| pubmed-article:2313733 | pubmed:author | pubmed-author:GordonG GGG | lld:pubmed |
| pubmed-article:2313733 | pubmed:author | pubmed-author:DonehowerR... | lld:pubmed |
| pubmed-article:2313733 | pubmed:author | pubmed-author:DavidsonN ENE | lld:pubmed |
| pubmed-article:2313733 | pubmed:author | pubmed-author:BeveridgeR... | lld:pubmed |
| pubmed-article:2313733 | pubmed:author | pubmed-author:WaterfieldW... | lld:pubmed |
| pubmed-article:2313733 | pubmed:author | pubmed-author:FettingJ HJH | lld:pubmed |
| pubmed-article:2313733 | pubmed:author | pubmed-author:DamronD JDJ | lld:pubmed |
| pubmed-article:2313733 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2313733 | pubmed:day | 4 | lld:pubmed |
| pubmed-article:2313733 | pubmed:volume | 82 | lld:pubmed |
| pubmed-article:2313733 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2313733 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2313733 | pubmed:pagination | 570-4 | lld:pubmed |
| pubmed-article:2313733 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:meshHeading | pubmed-meshheading:2313733-... | lld:pubmed |
| pubmed-article:2313733 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2313733 | pubmed:articleTitle | Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. | lld:pubmed |
| pubmed-article:2313733 | pubmed:affiliation | Oncology Center, Johns Hopkins University School of Medicine, Baltimore, MD. | lld:pubmed |
| pubmed-article:2313733 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2313733 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2313733 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2313733 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2313733 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2313733 | lld:pubmed |
